Home > Insider Trading > Filing (0001144204-17-065714)

Filing Details

Accession Number:: 0001144204-17-065714
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-12-29 07:38:46
Reporting Period:: 2017-12-22

Accepted Time:: 2017-12-29 07:38:46
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1279695	Universal Biosensors Inc	UBI	Surgical & Medical Instruments & Apparatus (3841)	980424072

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1678533	E. Craig Coleman	1 Corporate Avenue Victoria C3 3178		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-12-22	134,451	$0.27	28,097,902	No	4	P	Indirect	By Partnership
Common Stock	Acquisiton	2017-12-27	224,982	$0.29	28,322,884	No	4	P	Indirect	By Partnership
Common Stock	Acquisiton	2017-12-28	201,498	$0.29	28,524,382	No	4	P	Indirect	By Partnership
Common Stock	Acquisiton	2017-12-29	3,001,271	$0.30	31,525,653	No	4	P	Indirect	By Partnership

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Partnership
No	4	P	Indirect	By Partnership
No	4	P	Indirect	By Partnership
No	4	P	Indirect	By Partnership

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	220,000	Indirect	By the Coleman Super Fund

Footnotes

Traded as Chess Depository Interests ("CDIs") on the Australian Stock Exchange. CDIs represent beneficial interests in the common stock held by CHESS Depository Nominees Pty Ltd.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.265 to $0.270, inclusive. The Reporting Person undertakes to provide to Universal Biosensors, Inc. ("UBI"), any security holder of UBI, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.275 to $0.300. The Reporting Person undertakes to provide to Universal Biosensors, Inc. ("UBI"), any security holder of UBI, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.290 to $0.300. The Reporting Person undertakes to provide to Universal Biosensors, Inc. ("UBI"), any security holder of UBI, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions all at a price of $0.300. The Reporting Person undertakes to provide to Universal Biosensors, Inc. ("UBI"), any security holder of UBI, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.
The price per share of the common stock reported is stated in Australian dollars, as converted from a U.S. dollar price on the date of the transaction.
The Reporting Person is a director of Viburnum Funds Pty Ltd ("Viburnum"), which is the manager of each of VF Strategic Equities Fund ("Strategic Fund") and VF High Conviction Fund ("Conviction Fund"), the direct beneficial owners of the common stock. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of the common stock held by Strategic Fund and Conviction Fund, except to the extent of his pecuniary interest therein.
Viburnum, as the manager of Strategic Fund and Conviction Fund, may be deemed to beneficially own 31,525,653 shares of common stock, which consists of 20,091,652 and 11,434,001 shares of common stock held by Strategic Fund and Conviction Fund, respectively. Viburnum, as the manager of each of Strategic Fund and Conviction Fund, shares voting and dispositive power over, and may be deemed to beneficially own, the common stock held by the foregoing entities. The Reporting Person shares voting and dispositive power over, and may be deemed to beneficially own, the common stock held by the foregoing entities due to the Reporting Person serving as a director of Viburnum.
Craig E. and Phylis Coleman are the trustees of the Coleman Super Fund, of which Mr. Coleman is a potential beneficiary.